A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Patients With Chronic Heart Failure and Reduced Ejection Fraction

Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Enalapril
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms PARADIGM-HF
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 12 Oct 2017 Results assessing potential mortality reduction with optimal usage of sacubitril/valsartan therapy for the treatment of heart failure in mexico, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 12 Oct 2017 Results assessing potential mortality reduction with optimal usage of sacubitril/valsartan therapy for the treatment of heart failure in chile, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 19 Sep 2017 According to a Novartis media release, results from this trial are being presented at the Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top